The pandemic has given us the opportunity to reclaim our spot in the APIs market and not repeat the mistakes of the past
In Conversation
Despite the projected GDP growth since 2020 in most of [LatAm], existing healthcare budgets and reforms are no longer adept at addressing the unmet needs, creating…
Our view is that all stakeholders – not just payers – have responsibility for ensuring access, meaning that building on strong collaborations and public-private partnerships will be…
Two LatAm countries – Colombia and Mexico – are [MSD's] top clinical trial patient enrollers worldwide, and LatAm makes up approximately 15 percent of our total…
Despite the uncertainty of [LatAm] markets - due to inflation, political issues or even social ones - these challenges are what make us stronger and perform…
Healthcare sustainability depends on breaking down silos, bringing all stakeholders together with the patient at the centre to deliver mutual benefit. If the patient – who…
Latin America offers companies the opportunity to perform well and generates excellent performance examples to showcase around the world
[The dengue vaccine] is a momentous achievement for Takeda and will have a big impact on LatAm, which – along with Asia – is home to…
DIA today is a vastly different organization than it was. Our emphasis on catalyzing thought leadership and applying our global platform and channels to convene, conduct…
The issue of health is simply not a priority for the government. This is evident through the way they minimise many important aspects of the process…
In Mexico 85 percent of the medicines consumed by the population are produced in the country itself. For this reason, Mexico is considered one of the…
LatAm has an ethnically diverse population, strong doctor-patient relationships, and great clinical research centres, all of which are increasingly attracting the eye of our member companies…
